Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 May:79:104034.
doi: 10.1016/j.ebiom.2022.104034. Epub 2022 Apr 27.

Predicting the efficacy of new coronavirus vaccines - Are neutralising antibodies enough?

Elizabeth Miller  1
Affiliations
Comment

Predicting the efficacy of new coronavirus vaccines - Are neutralising antibodies enough?

Elizabeth Miller. EBioMedicine. 2022 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The author has no conflicts of interest

Comment on

References

    1. Khoury D.S., Cromer D., Reynaldi A., et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–1211. doi: 10.1038/s41591-021-01377-8. Epub 2021 May 17. PMID: 34002089. - DOI - PubMed
    1. Muena N.A., García-Salum T., Pardo-Roa C., et al. Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naïve and previously infected individuals. EBioMedicine. 2022;78 doi: 10.1016/j.ebiom.2022.103972. Epub ahead of print. PMID: 35366624; PMCID: PMC8965458. - DOI - PMC - PubMed
    1. Jara A., Undurraga E.A., Gonzalez C., et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N Engl J Med. 2021;385(10):875–884. 2022. - PMC - PubMed
    1. Fadlyana E., Rusmil K., Tarigan R., et al. A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: an interim analysis in Indonesia. Vaccine. 2021;39(44):6520–6528. doi: 10.1016/j.vaccine.2021.09.052. - DOI - PMC - PubMed
    1. Tanriover M.D., Doğanay H.L., Akova M., et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398(10296):213–222. Epub 2021 Jul 8. Erratum in: Lancet. 2022 Jan 29;399. - PMC - PubMed